Bone Morphogenetic Proteins (BMPs)
. In both mechanisms, the induction of bone and cartilage occurs through an epithelial-mesenchymal interaction (51) that initiates specific cell differentiation and leads to precursor cells of the osteoblastic or chondroblastic lineage. The development of cartilage and bone from mesenchyme, is characterized initially by a condensation of mesenchymal cells (52). This condensation can occur in two ways: either by cells moving toward a central focal point or by a localized region of increased proliferation. Direct cell-to-cell contact, diffusible molecules produced by the signaling cells, or matrix mediated interactions can result in a cellular mass of increased proliferative activity (53-55). An early step in the endochondral bone formation process is the condensation of mesenchymal cells into discrete pre-cartilaginous nodules. Chondrogenic cells become hypertrophic and pass into a bio-synthetically active state that involves mineral deposition in the cartilaginous matrix. The hypertrophic chondrocytes will then secrete chemotactic agents that both attract and direct the invasion of the sites by blood vessels. The chondrocytes eventually die and their matrix is partially destroyed during vascular invasion, which is when osteoblasts appear. Initially, osteoid will be deposited and remodeling will finally produce functional bone tissue (56). Guided streaming of specific cell types into the appropriate pathways makes BMPs important regulators of bone formation (113), with a pivotal role in bone remodeling (110). "Basic Multicellular Units" (BMUs) refer to the functional units of bone in which osteoblasts and osteoclasts act in coordination (115). This is called coupling. During remodeling, which is a "self-maintenance" process, existing bone is resorbed and new bone is deposited. Resorption during each remodeling cycle is balanced by an equal amount of bone formation since the amounts of BMPs and other growth factors released from bone are proportional to the extent of resorption (116,117). There is evidence that BMP-2 promotes expression of cyclooxygenase-2 and the osteoclast differentiation factor in osteoblast-like cells, thus regulating osteoclastogenesis (118). Based on the above, the mitogenic, chemotactic and differentiating effect of BMPs may help to mediate coupling of bone formation to resorption during the adaptive response of remodeling. It supports the cellular components and amplifies the molecular signals needed for the coordinated interaction of various cell types.
BMPs in fracture healing Fracture healing involves complex interactions among many local and systemic regulatory factors as well as cell types that cluster at the fracture site. Fracture repair represents a situation in which cell differentiation is reinitiated in an otherwise mature organism (2). Mesenchymal stem cells congregate at the area and form a gap-spanning, highly cellular "repair blastema" (119,120). The principal phases during ectopic bone induction are the migration and attachment of progenitor mesenchymal cells, proliferation, differentiation into cartilage or bone cell lineages, mineralization and remodeling, and marrow tissue formation.
The first demarcation of osteoprogenitor cells during fracture repair, referred to as the "stacked-cell layer" (120), is derived from mesenchymal stem cells (119). They are brought into the fracture area under the influence of paracrine or autocrine mechanisms (121) and then differentiate into pre-osteoblasts. In the case of bone fracture where there is a substantial gap between the originally continuous bone, a sequence of cellular and molecular events is initiated in response to the trauma, including inflammation, repair and remodeling (122). Injury leads to blood-clot formation that results in lysis of platelets, releasing numerous growth factors. The blood clot then begins to organize and the formation of a provisional callus that bridges the fracture site becomes apparent. Increased vascular permeability allows fluid and plasma proteins to leave the blood vessels. Various it in two phases: an initial phase within hours of implantation and a second phase that depends on the nature of the carrier and its geometrical characteristics (152) . It is believed that BMPs do not bind to the carrier (152), but rather become physically entrapped in its structure which makes certain designs more favorable for bone induction over some others (153) . In the case of collagen sponge carriers, the mass, collagen cross-linking and sterilization methods affect BMP precipitation and subsequent resistance of sponge degradation by collagenase (154) . Properties of the best carrier may vary depending on the specific implantation site and the intended therapeutic outcome. Considerations include biodegradability, structural integrity, absence of immunogenicity, absorption and rate of release of BMP (155) . The latter characteristic of the carrier serves its second function, which is controlled release of the BMP. This allows for a more constant and prolonged application. This renders BMPs more efficient and helps to create the chemotactic gradient, necessary for the cells to respond (11). BMP-2 is retained in a hydrogel carrier for more than 30 days whereas direct injection results in its complete elimination within 3 days (156) . Collagen carrier also resulted in increased bone density of the regenerate when compared to polymeric matrix (157) , emphasizing the importance of the structural properties of the carrier.
Recently, a novel approach has been suggested. This involves implanting matrices that actively concentrate native BMPs at the implantation site instead of passively storing and delivering rhBMPs which are a thousand times less potent that the native BMP complex (158) . The matrix also serves as an environment in which bone can form and therefore helps to define the region in which new bone can be formed (159) . Delivery vehicles with adequate structural consistency can function as primary scaffolds on which cells can attach and ECM, with subsequent mineralization, can be deposited (152, 160) . If the delivery matrix can act as a scaffold, then the cartilaginous intermediate may not be necessary. Many investigators agree that it has not been proved definitively that the chondrogenic process is essential for bone formation by BMP (89,161). The type of matrix used may also influence and determine the mechanism of bone formation that is appropriate for the implantation site (146). The material of the matrix and its geometrical parameters (pore size, and %volume) are factors that directly (size of cells able to attach) or indirectly (effect on blood or oxygen supply) determine the microenvironment and influence the mechanism of bone formation (endochondral or intramembranous) (59,89,90). BMPs combined with porous particles of hydroxyapatite or fibrous collagen membrane lead to intramembranous ossification (89,142,161), whereas fibrous glass membrane or insoluble bone matrix support indirect bone formation via a cartilaginous intermediate (89,90,142) .
In examining the action of BMPs, it is also important to consider dose-related effects. It is evident that various doses elicit different responses on specific cell types at different time intervals (162) . The dose of the growth factor determines its chemotactic, proliferative or mitogenic signal and should therefore be well regulated. Increased BMP concentrations result in faster bone growth (11), with cartilage being more rapidly replaced by mineralized osteoid (163) . rhBMPs in the form of monomers, homodimers or heterodimers need to be evaluated and standardized because they exhibit different biological potencies (11,121).
The carrier may also act synergistically by serving as a reservoir of the inducible cell population. Bone marrow can be combined with BMPs (164) and, when providing its cellular component, can result in bone formation of superior performance. Recently, investigators attempted the direct (in vivo) or indirect (using viral vectors) delivery of BMP genomic sequences to the implantation site (165, 166) , demonstrating active BMP expression for 2-6 weeks and bone formation with trabeculae and bone marrow. Cost of manufacturing and handling, in addition to ease of clinical application, are equally important factors to consider when deciding on a specific type of delivery vehicle.
Clinical applications BMPs are of tremendous interest as therapeutic agents for healing bone fractures, preventing osteoporosis, treating periodontal bone defects and enhancing bone response around alloplastic materials implanted in bone (3). rhBMP-2 delivered with an absorbable collagen sponge (ACS) has been used for the augmentation of the maxillary sinus floor in humans (167) . An rhBMP-2 dose ranging from 1.77 to 3.4mg per patient generated an average of 8.51 mm of vertical bone height in four months providing a promising alternative to traditional grafting procedures (167) . Similar results were also achieved in sub-antral augmentation of non-human primates with 6 mm of vertical bone gain and increased density that allowed placement of titanium implants (168) . BMP-2 regenerated bone in irradiated tissues also provides the clinical potential to treat patients who have undergone radiation therapy and need bone reconstruction (169) .
Periodontal regeneration was achieved when rhBMP-2 was applied to the defect site with a collagen membrane or a collagen gel. However, better results were obtained using the slower dissolving collagen membrane that allowed delivery of the growth factor for a prolonged period of time (170) . The clinical outcome was a decreased depth of the defect site brought about by stimulating vertical bone growth and regenerating the periodontal attachment, provided that adequate space is maintained (171) (172) (173) (174) (175) . The type of carrier, the time of treatment and the use of a barrier membrane are critical factors influencing the therapeutic outcome in cases of bone regeneration around dental implants (157) and have been shown to produce accelerated healing time as well as improved bone-implant contact levels (175) (176) (177) (178) (179) . Moreover, alveolar ridge preservation or localized augmentation have been documented in humans (180) .
Animal studies also suggest that rhBMP-2/ACS may be an effective treatment for the restoration of segmental bone defects (181, 182) and could lead to increased callus volume (183) , strength and stiffness (184) . A bioerodible polymeric carrier was used to deliver rhBMP-2 in a large segmental defect that was stabilized with stainless steel plates (185) . Stabilization was necessary because of the large size of the animals (sheep) but it could have also helped to provide a stable environment for bone bridging since the carrier was reported to fragment easily. In a similar study in rabbits, porous poly-lactic acid carrier combined with rhBMP-2 was found to restore cortical bone with marrow elements in a twenty-millimeter long segmental defect (186) . Skull defects were also filled with regenerated bone when BMPs were delivered in combination with hydroxyapatite (2,187), a biodegradable gelatin hydrogel or an aqueous solution (188) . Spinal fusion was significantly enhanced when rhBMP-2 was administered with a hydroxyapatite graft or a collagen gel, and demineralized bone matrix revealed improved biomechanical properties and enhanced radiographic and histologic appearance (189) .
Although purification and characterization of rhBMP-2 has been described in the Chinese hamster ovary (CHO) cell line (64) rendering BMPs available in large quantities, the fact that their inductive activity is ten times less than that of purified BMPs may present a limitation for their clinical application (190) . Combinations of BMPs with other growth factors or biologic molecules forming heterodimers with twenty times higher potency in some cases (191) than homodimeric forms, hold a promising future in the field of bioengineering.
The parameter of host age further affects the biologic potential of many growth factors (161) . The bone inductive ability of BMP-2 is diminished in older organisms and higher doses are required to induce the bone formation effect (192) . Reduced migration of mesenchymal cells, lower levels of local anabolic agents, age associated reduction of receptor levels and compromised vascularization are some of the aspects to take into consideration (193) (194) (195) . In the future, delivery of biological agents that control the regulators of BMPs may be of clinical significance in cases where BMP action needs to be halted to prevent pathological or hazardous ossification, such as after total hip or temporomadibular arthroplasties (44). Production of natural autogenous bone in moulds may allow a more efficient reconstruction of defects and deformities. H, Nakajima T, Ozawa H (1996) Long-term evaluation of recombinant human bone morphogenetic protein-2 induced bone formation with a biologic and synthetic delivery system. Br J
